Greenphire CEO, Jim Murphy, Named To Pharmavoice 100

(MENAFN- PR Newswire) Executive acknowledged for revolutionizing clinical trial financial
management process and enhancing patient access and convenience

KING OF PRUSSIA, Pa., Sept. 19, 2023 /PRNewswire/ -- Greenphire , the global leader in patient convenience and financial
lifecycle management for clinical trials, announced that its Chief Executive Officer, Jim Murphy, has been named to the PharmaVoice 100 list, which recognizes pioneers at the forefront of the life sciences industry

Murphy has led Greenphire in revolutionizing patient convenience and payment automation
in clinical trials. Since joining Greenphire in 2015, Jim has transformed the company from a young startup to today's market
leader. Under Murphy's stewardship, Greenphire has partnered with the most discerning sponsors of clinical research, with whom it has established enterprise relationships, such as the one most recently announced with Merck . Additionally, under Murphy's leadership, Greenphire has deepened its suite of solutions to further address evolving industry
needs and key challenges across the clinical trial lifecycle. This has included building out ConneX, a global travel
solution that addresses participant access and retention through an array of local and global travel
support capabilities; EnvisiX, a budget development and negotiation tool that accelerates this complex pre-trial phase and brings sponsors closer to FPI; and most recently GreenSpace, a mobile patient experience platform
which supports convenience, engagement, and retention.

"It's an honor to be named to the PharmaVoice 100, especially alongside such remarkable industry
leaders who are shaping the future of medical innovation," said Murphy. "At Greenphire, I am proud to lead a company whose sole focus is streamlining the business of clinical trials, so that our clients can successfully deliver new treatments and cures to those who need them – faster."

Having begun his career as a clinical research associate working directly with research sites, Murphy has dedicated his career to optimizing clinical trial execution and efficiency through technology
and service solutions. By reducing research site burden and complexity, site staff can spend more time on participant care and less on trial administration. This philosophy has contributed to Greenphire's unprecedented 91% global site satisfaction rating year over year for its flagship patient convenience offering, ClinCard.

The PharmaVoice 100 celebrates pioneers in the field of life sciences who are leading the way in industry
trends. These individuals are leaders who exceed expectations to propel the industry
forward, all the while leaving a profound and enduring influence on their respective companies, peers, communities, or scientific undertakings. They are trailblazers who have dedicated their professional journeys to the betterment of patients.

To see the full list of PharmaVoice 100 honorees, visit:

About Greenphire

Greenphire's suite of best-in-class technology
solutions enables clients to prioritize the patient journey, so treatments and cures can be delivered to those who need them faster.

Committed to modernizing and integrating each step in the participant journey and the overall clinical trial lifecycle, Greenphire has established an unmatched suite of patient convenience solutions, including a mobile-enabled technology
which offers a personalized and empowering end-to-end participant experience from trial identification through participation. ClinCard® and ConneX® remove financial
and logistical barriers, simplifying the delivery of global patient convenience initiatives and improving recruitment and retention. Greenphire's EnvisiXTM and eClinicalGPS® transform the budgeting and site payment process, resulting in expedited study start up and improved site sustainability. Learn more at .

Lindsay Hull
Zer0 to 5ive for Greenphire
Lindsay@0to5. com

SOURCE Greenphire


PR Newswire

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.